285 related articles for article (PubMed ID: 33570765)
1. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.
Vachon H; Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Fortpied C; Flechtner HH; Vestmoe Maraldo M; Hutchings M; Meijnders P; Aleman B; Lugtenburg P; Spina M; André M; Hertzberg M; Briones J; Bottomley A;
Eur J Haematol; 2021 May; 106(5):697-707. PubMed ID: 33570765
[TBL] [Abstract][Full Text] [Related]
2. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population.
Pilz MJ; Loth FLC; Nolte S; Thurner AMM; Gamper EM; Anota A; Liegl G; Giesinger JM;
J Patient Rep Outcomes; 2024 May; 8(1):48. PubMed ID: 38695992
[TBL] [Abstract][Full Text] [Related]
3. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
[TBL] [Abstract][Full Text] [Related]
4. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.
Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Pogoda K; Velikova G; Bjelic-Radisic V; Cardoso F; Brain E; Ignatiadis M; Piccart M; Van Tienhoven G; Mansel R; Wildiers H; Bottomley A;
Eur J Cancer; 2020 Jan; 125():69-82. PubMed ID: 31838407
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values.
Amin S; Joo S; Nolte S; Yoo HK; Patel N; Byrnes HF; Costa-Cabral S; Johnson CD
BMC Cancer; 2022 May; 22(1):563. PubMed ID: 35596182
[TBL] [Abstract][Full Text] [Related]
6. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27.
Oerlemans S; Efficace F; Shamieh O; Cardoso Borges F; de Jong C; Dong D; Lehmann J; Malak S; Petranovic D; Scholz CW; Caocci G; Molica S; Griskevicius L; Nagele E; Bredart A; Carvalho E; Xochelli A; Agelink van Rentergem J; Alrjoob W; Mueller A; Freitas AC; Cocks K; Creutzberg C; Kyriakou C; van de Poll-Franse L
Blood Adv; 2023 Nov; 7(22):7045-7055. PubMed ID: 37738090
[TBL] [Abstract][Full Text] [Related]
7. International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S; Efficace F; Kyriakou C; Freitas AC; Shamieh O; Creutzberg CL; Lehmann J; Petranovic D; Nagele E; Bredart A; Dong D; Scholz CW; Caocci G; Molica S; Griskevicius L; Xochelli A; Kieffer JM; Agelink van Rentergem JA; Alrjoub W; Mueller A; Gomes Da Silva M; Alves da Costa F; Malak S; Cocks K; van de Poll-Franse LV;
Cancer; 2023 Sep; 129(17):2727-2740. PubMed ID: 37204189
[TBL] [Abstract][Full Text] [Related]
8. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
de Ligt KM; Aaronson NK; Liegl G; Nolte S;
Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
[TBL] [Abstract][Full Text] [Related]
9. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Heutte N; Flechtner HH; Mounier N; Mellink WA; Meerwaldt JH; Eghbali H; van't Veer MB; Noordijk EM; Kluin-Nelemans JC; Lampka E; Thomas J; Lugtenburg PJ; Viterbo L; Carde P; Hagenbeek A; van der Maazen RW; Smit WG; Brice P; van Marwijk Kooy M; Baars JW; Poortmans P; Tirelli U; Leeksma OC; Tomsic R; Feugier P; Salles G; Gabarre J; Kersten MJ; Van Den Neste E; Creemers GJ; Gaillard I; Meijnders P; Tertian G; Reman O; Muller HP; Troncy J; Blanc M; Schroyens W; Voogt PJ; Wijermans P; Rieux C; Fermé C; Henry-Amar M;
Lancet Oncol; 2009 Dec; 10(12):1160-70. PubMed ID: 19828373
[TBL] [Abstract][Full Text] [Related]
10. Population-based reference values for the European Organization for Research and Treatment of Cancer Head and Neck module.
Hammerlid E; Adnan A; Silander E
Head Neck; 2017 Oct; 39(10):2036-2047. PubMed ID: 28708279
[TBL] [Abstract][Full Text] [Related]
11. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
12. Normative data for the EORTC QLQ-C30 from the Austrian general population.
Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
[TBL] [Abstract][Full Text] [Related]
13. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group.
Kreissl S; Müller H; Goergen H; Meissner J; Topp M; Sökler M; Markova J; Bernhard J; Greil R; von Tresckow B; Behringer K; Rüffer JU; Flechtner HH; Möstl M; Fuchs M; Engert A; Diehl V; Borchmann P
J Clin Oncol; 2020 Sep; 38(25):2839-2848. PubMed ID: 32574114
[TBL] [Abstract][Full Text] [Related]
15. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
van de Poll-Franse L; Oerlemans S; Bredart A; Kyriakou C; Sztankay M; Pallua S; Daniëls L; Creutzberg CL; Cocks K; Malak S; Caocci G; Molica S; Chie W; Efficace F;
Qual Life Res; 2018 Feb; 27(2):333-345. PubMed ID: 29127596
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
17. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity.
Juul T; Petersen MA; Holzner B; Laurberg S; Christensen P; Grønvold M
Qual Life Res; 2014 Oct; 23(8):2183-93. PubMed ID: 24676897
[TBL] [Abstract][Full Text] [Related]
18. EORTC QLQ-C30 normative data for the United Kingdom: Results of a cross-sectional survey of the general population.
Young T; Velikova G; Liegl G; Rose M; Nolte S;
Eur J Cancer; 2024 Jun; 204():113927. PubMed ID: 38429166
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
20. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
